Sugammadex versus neostigmine for early lung function recovery after thoracoscopic segmentectomy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In a multicenter, randomized, double-blind trial, 240 adults (ASA I–III) undergoing elective unilateral thoracoscopic lung segmentectomy (≤1 segment) will be assigned 1:1 to receive either sugammadex (2 mg/kg) or neostigmine (0.03 mg/kg) plus atropine (0.015 mg/kg) at the end of surgery. Pulmonary function will be measured with a portable spirometer before surgery and at 1 hour post-extubation and on postoperative days 1–3, with the primary endpoint being percent decline in FEV1 at 1 hour versus baseline. Secondary outcomes include FEV1 over days 1–3, pain scores, opioid use, pulmonary complications, and PACU/hospital recovery metrics. The study tests the hypothesis that sugammadex leads to at least a 5% smaller decline in FEV1 at 1 hour compared with neostigmine.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Scheduled for elective unilateral thoracoscopic partial lung resection, with expected resection not exceeding one lung segment.
* Age between 18 and 80 years.
* American Society of Anesthesiologists (ASA) Physical Status classification I-III.

Exclusion Criteria:

* Contraindications to drug use, such as history of allergy, epilepsy, angina, ventricular tachycardia; contraindicated in patients with mechanical intestinal obstruction or urinary tract obstruction; contraindicated in cases of arrhythmia, bradycardia (\<50 beats per minute), hypotension, or increased vagal tone; contraindicated in patients currently using depolarizing muscle relaxants (e.g., succinylcholine).
* Inability to correctly cooperate with portable lung function testing.
* Hepatic or renal insufficiency.
* Pregnancy, lactation, potential for pregnancy, or planning pregnancy.
* Preoperative history of drug abuse or addiction.
* Second surgery during postoperative hospitalization.
* Patients who refuse to participate.
* Other situations deemed inappropriate by the investigators shall be accompanied by a statement of the reasons.

Where it's running

• Shanghai Pulmonary Hospital
  Shanghai, Shanghai Municipality, China Recruiting
• Shanghai East Hospital,Affiliated to Tongji University
  Shanghai, Shanghai Municipality, China Recruiting
• Fudan university Shanghai cancer center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Shiyou Wei, PhD
• Email: lovewishyou@163.com
• Phone: 8615601680288

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NMTCuff vs standard TOF monitoring during gynecologic oncology surgery

  This study tests whether NMTCuff monitoring can better detect neuromuscular recovery than standard TOF monitoring in women undergoing laparoscopic gynecologic cancer surgery.

  Recruiting Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital · Ankara · NCT07925463

• Becotatug Vedotin in relapsed SCLC: a single-center examine-what-works

  This study tests whether becotatug vedotin helps people whose small cell lung cancer has come back after prior treatment.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai · NCT07874581

• Neoadjuvant PD-L1/VEGF Bispecific Antibody with Chemo versus Chemo plus PD-1 Monoclonal Antibody in Locally Advanced NSCLC

  In people with locally advanced NSCLC, this study tests whether adding a PD-L1/VEGF bispecific antibody to chemotherapy before surgery improves outcomes compared with a PD-1 antibody added to chemotherapy.

  Recruiting at 2 sites Phase 3 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, China and 4 other locations · NCT07863999

• Biologics for Type 2 Inflammation in Asthma and COPD in Real World

  This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07823842

• Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients

  This observational study tests how fast patients with IPF or PPF can inhale through dry powder inhalers with different resistances.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07820254

• Oral Paclitaxel with Immunotherapy and SBRT as Neoadjuvant Treatment for Older Adults with NSCLC

  This trial tests a new, lighter neoadjuvant therapy that combines an oral paclitaxel solution, an immune checkpoint inhibitor, and SBRT for adults aged 70 and older with resectable NSCLC to see if it can shrink tumors before surgery.

  Recruiting Phase 4 Shanghai Pulmonary Hospital, Shanghai, China · Guangzhou, Guangdong and 4 other locations · NCT07754812

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.